How to appeal a Horizon Blue Cross Blue Shield of New Jersey continuous glucose monitors & insulin pumps denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Horizon Blue Cross Blue Shield of New Jersey-specific note: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).

What Horizon Blue Cross Blue Shield of New Jersey's policy requires for continuous glucose monitors & insulin pumps

Cited policy: BCBS Medical Policy - External Insulin Pump / Hybrid Closed-Loop

T1DM or insulin-requiring T2DM (with C-peptide); AID systems covered when FDA-cleared.

How Horizon Blue Cross Blue Shield of New Jersey denies continuous glucose monitors & insulin pumps — and how to counter it

Where Horizon Blue Cross Blue Shield of New Jersey pushes back: 1) 'Try MiniMed 670G or 770G before 780G'; 2) 'SmartGuard auto-bolus too aggressive'; 3) 'No clinical advantage over predicate'.

Counter-arguments that hold up: MiniMed 770G has been discontinued by Medtronic; 670G is two generations old. 780G + Guardian 4 FDA-approved Apr 21, 2023 with meal-detection auto-correction every 5 min — first AID with this feature. ADAPT (Choudhary P et al., Lancet Diabetes Endocrinol 2022;10:720-731): 1.4% A1c reduction and 27.6% TIR improvement vs MDI+isCGM at 6 months, sustained at 12 months, no DKA or severe hypo. Auto-correction is the mechanism of benefit, not a safety risk.

What Horizon Blue Cross Blue Shield of New Jersey typically denies for continuous glucose monitors & insulin pumps

Across Horizon Blue Cross Blue Shield of New Jersey's commercial and Medicare books, denials cluster around a small number of patterns. For continuous glucose monitors & insulin pumps, expect:

• OMNIA tier-1 vs tier-2 provider disputes
• Step therapy on biologics
• Behavioral health prior auth
• Out-of-state emergency reductions

Treatments most often denied in this category

These are the continuous glucose monitors & insulin pumps treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dexcom G7
• Dexcom G6
• Libre 3 Plus
• Libre 2 Plus
• Eversense 365
• Tandem t:slim X2

How to submit the appeal to Horizon Blue Cross Blue Shield of New Jersey

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Horizon Blue Cross Blue Shield of New Jersey cited in the denial.
3. File the appeal through Horizon Blue Cross Blue Shield of New Jersey's portal (members: https://www.horizonblue.com ; providers: https://www.horizonblue.com/providers). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In NJ, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Horizon Blue Cross Blue Shield of New Jersey's prior-authorization criteria by drug: Horizon Blue Cross Blue Shield of New Jersey PA criteria on ApprovalHelp.